// App-Quantinova.ai

8042 : Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Researchers

Presenter

  • Ivan Spicka

Principal Investigators

  • Philippe Moreau

  • Thomas G. Martin

  • Thierry Facon

  • Gracia Martinez

  • Albert Oriol

  • Youngil Koh

  • Andrew Lim

  • Gabor Mikala

  • Laura Rosiol

  • Mnci Yagci

  • Michele Cavo

  • Marie-Laure Risse

  • Galle Asset

  • Sandrine Mac

  • Helgi Van De Velde

  • Kwee Yong

Medical Centers

  • Clinical Department of Hematology, 1st Medical Department, Charles University, Prague, Czech Republic, University of Nantes, Nantes, France

  • University of California, San Francisco, San Francisco, CA

  • Department of Biology, Lille University Hospital, Lille, France

  • Hospital das Clinicas de Sao Paulo - ITACI, Sao Paulo, Brazil

  • Institut Catala dOncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

  • Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia

  • National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary

  • Hospital Clinic, IDIBAPS, Barcelona, Spain

  • Ankara University, Ankara, Turkey

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • Sanofi R&D, Vitry-Alfortville, France

  • Sanofi, Chilly-Mazarin, France

  • Sanofi R&D, Vitry-Sur-Seine, France

  • Sanofi Onology, Cambridge, MA

  • Kings College London, London, United Kingdom

Locations

  • France

  • Brazil

  • Spain

  • Australia

  • Hungary

  • Turkey

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved